• IRulya Therapeutics expects Phase 2 data for inhaled rapamycin LAM-001 in bronchiolitis obliterans syndrome in the first quarter of 2027.
• The ongoing Phase 2b PH-ILD trial targets 75 patients, with data anticipated in the first quarter of 2028.
• A Phase 2 sarcoidosis-associated pulmonary hypertension trial is expected to start in the fourth quarter of 2026; data are anticipated in late 2028.
• Phase 2a PH-ILD patients recorded a mean 67.4-meter improvement in six-minute walk distance at 24 weeks; four patients were evaluable.
• An oversubscribed financing raised $115 million upfront in May 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRulya Therapeutics Inc. published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.